Stocks 20th Jan '25 Chinese Biotech Nearly a third of big pharma in-licensed molecules are sourced from China. Source: Stifel Biopharma Outlook 2025 (full deck). Click to share on Twitter (Opens in new window)Click to email a link to a friend (Opens in new window)Click to share on LinkedIn (Opens in new window)
